Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
15 participants
OBSERVATIONAL
2008-06-30
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
No evidence of efficacy is required to proceed to longer term studies; however, we will need to confirm lack of development of macrolide resistance in this pilot study before proceeding to any additional studies to evaluate the efficacy of short course MAC treatment.
Once we have demonstrated the feasibility of short course therapy and confirm that resistance to macrolides does not develop, we hope to apply for external funding to support a longer term randomized controlled trial comparing "standard" MAC therapy (which usually consists of a period of eighteen to twenty-four months with at least three antimicrobials) to short course (three months) MAC antimicrobial treatment, alternating each year with nine months of non-MAC bronchial hygiene measures for two consecutive years. If a larger study confirms efficacy of this approach, we would then propose even larger multi-site studies to test the hypothesis that short course MAC therapy alternating every year with non-MAC bronchial hygiene therapy should be considered in all adult patients with MAC pulmonary disease associated with multifocal bronchiectasis and multiple small nodules throughout their lives.
The longer term goal of this research is to develop an optimal treatment strategy for these patients (in whom MAC will likely persist indefinitely) that will result in not only a better quality of life, but less evidence of long term lung damage, less risk of drug-related morbidity, and be better tolerated by the patients compared to current treatment strategies.
The specific aims of this pilot study are as follows:
Primary Aim:
1. Confirm that macrolide (either Clarithromycin or Azithromycin) resistance does not develop as a result of short course treatment.
Secondary Aims:
2. Assess for change in quality of life metrics (St. George Respiratory Questionnaire and SF 12) from baseline to the conclusion of the study period (six months). We expect to see improvement in quality of life measures as a result of this short course treatment trial.
3. Assess for change in pulmonary function from baseline to the conclusion of the study period. We expect to see improvement particularly in the FEV1, FEV1/FVC, and diffusing capacity for carbon monoxide as a result of this short course treatment trial.
4. Assess for change in high resolution computerized tomography (HRCT) of the chest, evidence of MAC pulmonary disease (multifocal bronchiectasis associated with multiple small nodules) from baseline to the conclusion of the study period. We do not anticipate being able to demonstrate improvement in the HRCT evidence of MAC lung disease during the short period of this trial since these changes usually occur quite slowly.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Confirmation both by a chest radiologist and the investigators of multifocal bronchiectasis and multiple small nodules on HRCT scanning of the chest
3. Repeatedly positive sputum cultures and/or bronchial washings for MAC (in accordance with microbiologic diagnostic criteria outline by the American Thoracic Society)
4. MAC must be proven to be macrolide (either Clarithromycin or Azithromycin) sensitive at the onset of the study
5. Age greater than 18
6. No active treatment for MAC lung disease within the past two years
7. Patients and their physicians must be willing to discontinue other non-MAC antimicrobials which may have been used as part of their pre-study bronchial hygiene program.
Exclusion Criteria
2. Known allergy or intolerance to any of the proposed antibiotics
3. Inability to return at three month intervals for testing over the six month study period
4. Inability to complete quality of life questionnaires
5. Pregnancy
6. Presence of any abnormality on baseline ophthalmological examination which would preclude the use of ethambutol.
7. Coexistence of non-tuberculous mycobacteria other than MAC
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mayo Clinic
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jack P Leventhal, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic Assistant Professor of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-004414
Identifier Type: -
Identifier Source: org_study_id